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Abstract
Background: Standard treatment for patients with disseminated germ cell tumors is combination chemotherapy
with bleomycin, etoposide and cisplatin (BEP). This treatment is highly effective, but the majority of patients
experience severe adverse effects during treatment and are at risk of developing considerable long-term morbidity,
including second malignant neoplasms, cardiovascular disease, and pulmonary toxicity. One neglected side effect is
the significant muscular fatigue mentioned by many patients with testicular cancer both during and after
treatment. Very limited information exists concerning the patho-physiological effects of antineoplastic agents on
skeletal muscle. The primary aim of this study is to investigate the effects of BEP-treatment on the skeletal
musculature in testicular cancer patients, and to examine whether the expected treatment-induced muscular
deterioration can be attenuated or even reversed by high intensity progressive resistance training (HIPRT).
Design/Methods: The PROTRACT study is a randomized controlled trial in 30 testicular cancer patients undergoing
three cycles of BEP chemotherapy. Participants will be randomized to either a 9-week HIPRT program (STR) initiated
at the onset of treatment, or to standard care (UNT). 15 healthy matched control subjects (CON) will complete the
same HIPRT program. All participants will take part in 3 assessment rounds (baseline, 9 wks, 21 wks) including
muscle biopsies, maximum muscle strength tests, whole body DXA scan and blood samples. Primary outcome:
mean fiber area and fiber type composition measured by histochemical analyses, satellite cells and levels of protein
and mRNA expression of intracellular mediators of protein turnover. Secondary outcomes: maximum muscle
strength and muscle power measured by maximum voluntary contraction and leg-extensor-power tests, body
composition assessed by DXA scan, and systemic inflammation analyzed by circulating inflammatory markers, lipid
and glucose metabolism in blood samples. Health related Quality of Life (QoL) will be assessed by validated
questionnaires (EORTC QLQ-C30, SF-36).
Discussion: This study investigates the muscular effects of antineoplastic agents in testicular cancer patients, and
furthermore evaluates whether HIPRT has a positive influence on side effects related to chemotherapy. A more
extensive knowledge of the interaction between cytotoxic-induced physiological impairment and exercise-induced
improvement is imperative for the future development of optimal rehabilitation programs for cancer patients.
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Background
Testicular cancer (TC) is the most common form of
cancer among young men in western countries [1], and
remains the most curable solid tumor with a 10 year
survival of 90 to 95% [2]. The standard treatment for
patients with advanced germ cell cancer is 3 or 4 cycles
of chemotherapy with cisplatin, etoposide and bleomy-
cin (BEP) depending on prognostic factors. The treat-
ment is highly effective, but the majority of patients
experience severe adverse effects during treatment, and
are at risk of developing considerable long-term morbid-
ity, including second malignant neoplasms, cardiovascu-
lar disease, neurotoxicity, nephrotoxicity, pulmonary
toxicity, hypogonadism, decreased fertility, and psycho-
social problems [3]. In a study by Orre et al. the preva-
lence of chronic cancer related fatigue was 17.1% among
TC patients compared to 9.7% in the general population.
Regression analyses showed that poor quality of life
(QoL), various psychosocial and somatic problems, and
neuroticism were highly associated with presence of
chronic cancer related fatigue [4].
Impaired muscular function and significant muscular
fatigue are common complaints among TC patients
undergoing chemotherapy. The cause of this muscular
deconditioning is unknown, and knowledge regarding the
effect of antineoplastic drugs on muscle function and mor-
phology is very limited. There is also a lack of knowledge
regarding whether TC patients will benefit from exercise
training during chemotherapy.
The primary aim of the study is to investigate the
effects of BEP-treatment on skeletal muscle, and to
examine whether the treatment-induced muscular dete-
rioration can be attenuated or even reversed by high
intensity progressive resistance training (HIPRT) initiated
o nd a y1o ft h ec o u r s eo fa n t i n e o p l a s t i ct r e a t m e n t .W e
have chosen a type of resistance exercise program that
has proven to induce significant muscular hypertrophy in
both healthy and diseased subjects [5]. Furthermore, the
long term effect of an exercise rehabilitation program
after the course of treatment will be investigated.
Methods/Design
Participants and setting
Testicular cancer patients
30 patients with disseminated germ cell cancer, sched-
uled to initiate 3 cycles of BEP-chemotherapeutic treat-
ment at Rigshospitalet, Copenhagen, will be included in
the study. Further inclusion and exclusion criteria are
listed in table 1. The TC patients will be included and
baseline-tested before the start of the first cycle of BEP
treatment.
Healthy control subjects
15 healthy control subjects, matching TC patients in the
following parameters: age, BMI and exercise training his-
tory, will be included in the study. This intervention-arm
will represent the “standard” effect of HIPRT in young
men not affected by antineoplastic treatment. The study
will be conducted according to the CONSORT (Consoli-
dated Standards of Reporting Trials) statement for non-
pharmacological interventions[6], and has been approved
by the Regional Ethics committee for the Capital Region
(protocol nr: H-1-2010-049) and the Danish Data Protec-
tion Agency (jr.nr. 2010-41-5118).
Recruitment
The study flow is presented in Figure 1. TC patients (sub-
jects) will be recruited by clinicians at the Department of
Oncology, Rigshospitalet, Copenhagen. The primary
attending oncologist will present oral and written informa-
tion about the study to the eligible participant. Interested
participants will be contacted by the study coordinator,
who will answer any further questions. The participants
will be invited to visit the training facilities, before giving
their written consent.
The healthy control subjects will be recruited through
announcements in local newspapers and the internet.
Randomization
Following the baseline test, TC patients will be allocated to
either, STRength training (STR, n = 15), receiving a 9-wks
HIPRT-program during treatment, or UNTrained (UNT,
n = 15), who will receive standard care. The randomization
procedure used is a simple adaptive biased-coin randomi-
zation. The inclusion criteria (men, aged 18-45, same diag-
nosis/stage of disease and treatment protocol) secure
comparable groups in terms of sex, age and disease profile
at baseline, and therefore no stratification will be carried
out. The healthy CONtrol subjects (CON, n = 15) will be
allocated to HIPRT without randomization.
Blinding
Blinding of participants in this type of study is not possible
since participants will know whether they are exercising or
not. Nor are the training instructors blinded, since they
will know if they are instructing a patient undergoing che-
motherapy or a healthy control subject. However, study
personal doing baseline, post-intervention and follow-up
assessment will be blinded, as will laboratory personal
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samples). Only the study coordinator and leading oncolo-
gist will know which TC patients are allocated in which
groups.
Treatment
Antineoplastic treatment for TC patients consists of cis-
platin 20 mg/m
2 and etoposide 100 mg/m
2 daily for 5
days and bleomycin 15.000 IU/m
2 given weekly. Three
cycles of this combination are administered, with every
cycle lasting three weeks.
Intervention
The exercise intervention will be comprised of high
intensity progressive resistance training (HIPRT) with 3
training sessions pr week, as previously described by
Andersen and Aagaard [5]. In week 1 and 2 the partici-
pants will conduct 3 sets of 15 repetitions (reps) at a
15-repetition maximum (RM) intensity to become famil-
iarized with the exercises. From week 3 and onwards,
the participants will conduct 4 sets of 10 reps at 10-12
RM intensity. Progression will be assured, such that if
the participant can do more than 12 reps, the weight
will be increased. All exercises will be performed in a
supervised setting to ensure correct technique and
proper progression. This type of resistance exercise pro-
gram has been proven to induce significant muscle
hypertrophy in both healthy and diseased subjects [5].
Study arm 1: HIPRT for TC patients during and after BEP
treatment (STR)
This group will conduct a 9 week HIPRT-program,
initiated at day 1 of the treatment, and will be offered a
Table 1 Eligibility Criteria
Inclusion Criteria
Age: 18-45
Ability to read and understand Danish
Signed informed consent
Exclusion criteria
Presence of any type of current or previous malign disease
Presence of any type of cardiovascular disease (i.e. Cardiomyopathy, Coronary heart disease etc.)
Presence of any type of chronic disease (i.e. Diabetes mellitus, Chronic Obstructive Pulmonary Disease etc.)
Figure 1 Study Flow.
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chemotherapy.
Study arm 2: Usual care for TC patients during BEP
treatment and HIPRT as rehabilitation following treatment
(UNT)
This group will receive standard care for the 9 week
period during treatment, and will be offered a 12 week
rehabilitation-program with HIPRT after termination of
chemotherapy.
Study arm 3: HIPRT for healthy matched control subjects
(CON)
This group will conduct a 21 week HIPRT program fol-
lowing the same progression as STR.
Study Endpoints and Assessment
During the course of the study the participants will
carry out physical tests, have invasive biological samples
taken and complete standardized questionnaires. The
schedule for individual data assessment is presented in
table 2, and the study endpoints are summarized in
table 3.
The healthy control subjects will carry out the same
testing protocol and have the same biological samples
taken, but will not receive cancer specific questionnaires.
Primary outcome
Muscle biopsies will be collected from m. vastus lateralis
using the Bergstrom-technique [7]. The muscle samples
are immediately mounted with Tissue-Tek and frozen in
isopentane cooled with liquid nitrogen, and stored at
-80°C until further investigation. The post intervention
biopsy will be obtained at 1 cm either distally or proxi-
mally (randomized) to the baseline biopsy.
Mean fiber area and fiber type distribution will be ana-
lyzed as described by Andersen & Aaagaard [5]. Serial
sections (10 μm) of the muscle biopsy samples will be cut
in a cryostat (-20°C), and routine ATPase histochemistry
analysis will be performed after preincubation at pH 4.37,
4.60, and 10.30.
Number and activation status of satellite cells in mus-
cle biopsies will be assessed by immunohistochemistry, as
previously described by Mackey et al. [8]. The primary
antibodies for Pax7, Type I myosin (A4.951), and laminin
will be applied to the same section. In this approach, sites
of Pax7 antigenicity are visible by light microscopy while
fluorescence microscopy on the same section reveals
which fibres are type I and type II. The same sections can
be used to determine the number of myonuclei asso-
ciated with type I and type II fibres. Active satellite cells
can be distinguished from quiescent with the aid of dou-
ble staining for satellite cells and Ki67, as described [9].
Levels of Intracellular Signaling Molecules:G e n e
expression of different signalling molecules involved in
hypertrophy and atrophy, i.e. Insulin-like Growth Factor
1 (IGF-1) and Atrogin-1, will be measured by real-time
Reverse Transcription Polymerase Chain Reaction (RT-
PCR), as previously analyzed by our laboratory [10,11].
Secondary outcome
Physical function tests will include maximum isometric
quadriceps muscle strength test by maximum voluntary
contraction (MVC)-measurements using ‘Good
Strength’-chair, and maximum muscle power will be
assessed by Leg Extensor Power (LEP)-measurements in
Nottingham Power-Rig.
Maximum voluntary contraction: The participants will
be fixated in the Good Strength chair (Metitur Oy, FI-
40250 Jyväskylä, Finland. CE certificate: NB ID 0537)
with a fixed knee angle of 60 degrees (0 degree = full
extension) [12]. Maximum isometric muscle torque will
be assessed for both quadriceps (extension) and ham-
string (flexion) for both legs. Which leg will be tested
first will be randomly selected. A minimum of 3
attempts will be carried out for each leg, and the partici-
pants will continue until one attempt is lower than the
maximum. The overall maximum attempt (for both
legs) will be used as test result.
Leg Extensor Power: The participant is seated in the
Power Rig (Nottingham Power Rig, Queen’s Medical
Centre Nottingham, NG7 2UH, United Kingdom) with
joint angles as if the participant was rising from a chair.
The participants extend one leg as forcefully as possible,
and the velocity of the flywheel is measured by an
optoswitch and used to calculated the average leg exten-
sor power in the push [13]. Each leg is tested separately,
a minimum of 5 attempts is carried out for each leg,
Table 2 Data Assessment Schedule
Data assessment Baseline test
Day - 5-0
Treatment start
Day 1
2
nd cycle start
Day 22
3
rd cycle start
Day 43
Post interv. test
Day 64-66
Follow-up test
~ Day 150
Muscle biopsy x xx
Blood sample x x x x x
DXA scan x xx
Strength test x xx
Questionnaires
(SF 36 & EORTC)
xx x x x
Randomization x
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are lower than the maximum. The overall maximum
attempt for both legs is used as the test result.
Systemic inflammation, lipid and glucose metabolism
will be measured in fasting blood samples. The partici-
pants will arrive at the hospital after an overnight fast
(minimum 8 hours) and have a 10 ml venous blood sam-
ple drawn according to standard clinical guidelines.
Circulating cytokines will be analyzed in plasma using
ethylenediaminetetraacetate (EDTA) as an anticoagulant.
Plasma is stored at - 80 C until analysis. C-reactive Protein
(CRP), Tumor Necrosis Factor alpha (TNF-a), Interleu-
kin-6 (IL-6), Interleukin-18 (IL-18), Interleukin-4 (IL-4)
and Interleukin-10 (IL-10) are determined by enzyme-
linked immunosorbent assay (ELISA) kits, as previously
described by Lindegaard et al [14].
Total cholesterol (TCHO), high density lipoprotein
(HDL)-cholesterol, low density lipoprotein (LDL)-cho-
lesterol, triglycerides, glucose and Insulin are measured
using standard laboratory procedures.
Whole Body composition will be assessed by whole body
Dual-Energy X-ray Absorptiometry, (DXA scan) (DPX-IQ
Lunar, Lunar Corporation Madison, WI, USA). Transverse
scans at 1 cm intervals are made from head to toe measur-
ing the absorption of x-ray beams at two different energy
levels as these are sent through the body. Since the differ-
ent chemical compounds (bone, fat, and fat-free/bone-free
mass) in the body absorb the intensity of the X-rays differ-
ently, the scan allows for a valid determination of bone
mass, fat mass and fat-free/bone-free mass [15].
The DXA scans will be carried out in the morning
after an overnight fast. The participants will be asked to
standardize their food and water intake on the day prior
to scanning to minimize difference in overall hydration
as well as extra- and intracellular water distribution as
much as possible [16].
Patient reported outcomes related to Health Related
Quality of Life (QoL) will be assessed be standardized
questionnaires: European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire
(EORTC QLQ-C30) [17] and Medical Outcomes Study
Short Form (MOS SF-36) [18]. EORTC QLQ-C30 com-
prises five functional scales, nine symptom scales or items,
and a global health status/quality of life scale. A high score
on the functional and global health status/quality of life
scale represents a high or healthy level of functioning and
high quality of life, while a high score for a symptom scale
represents a high level of symptom burden. MOS SF-36
contains eight scales evaluating general health concepts
and two summary scales: physical component scale and
mental component scale.
Sample size
Sample size is chosen to ensure significant muscular
hypertrophy, evaluated by mean fiber area, in CON,
among whom a 15% increase is estimated according to
earlier studies.
N>( 1 , 2 8 * √(0.15*0.85))
2/(0.15
2) = 9,28. A minimum of
10 is required in each group, but due to clinical experience
concerning possible drop out due to medical reasons 15
are included in each group.
Analytic Plan
1-way repeated measures Analysis Of Variance (RM-
ANOVA) will be used to evaluate test-data within groups
for assessments at baseline, 9 and 21 weeks. 2-way
ANOVA (group × time) will be used to test the effect of
HIPRT for TC patients (STR vs. UNT), and BEP-treat-
ment for training response (STR vs. CON) respectively.
The equivalent non-parametric tests will be used for
mRNA expression and protein levels. Significance level of
0.05 is chosen.
Discussion
Exercise for cancer patients undergoing treatment with
chemotherapy has been shown to improve the patient’s
physical capacity and to reduce side effects such as fatigue
[19]. Recent studies have shown positive effects of exercise
on tumor-related outcomes, showing a direct link between
exercise induced cellular and systemic changes and
reduced tumor progression in breast cancer [20,21]. These
results underline findings in large population based studies
suggesting that physical activity level is inversely related to
mortality in both breast cancer and prostate cancer survi-
vors [22-24]. Consequently, exercise is now being recom-
mended both during and after cancer treatment [25].
Table 3 Study Endpoints
Muscular morphology
￿ Mean fiber area
￿ Fiber type distribution
￿ Satellite cells
￿ Intracellular signaling molecules
Body Composition
￿ Lean Body Mass
￿ Fat percentage
Muscle strength
￿ Maximum Voluntary Contraction
￿ Leg Extensor Power
Systemic effects
￿ Cholesterol (TCHO, HDL, LDL, Triglycerides)
￿ Glucose
￿ Insulin
￿ Inflammatory markers (CRP, TNF-a, IL-6, IL-18)
￿ Anti-inflammatory markers (IL-4, IL-10)
Patient reported outcomes
￿ Health related Quality of Life (SF-36 and EORTC)
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in exercise-oncology research. To our knowledge only 3
exercise studies for cancer patients undergoing che-
motherapy have included TC patients - these are data
from phase 1, 2 and 3 of the “Body and Cancer” study at
our institution [26]. The relative absence of TC patients in
exercise-oncology research is probably due to the low inci-
dence rate and good prognosis of this cancer diagnosis.
However, a compelling need exists to expand the research
related to the acute and late effects of testicular cancer
and its treatment, especially with regard to factors that
confer an enhanced susceptibility to the toxicities of cis-
platin-based chemotherapy. In addition to the extensive
degree of treatment induced toxicity resulting in severe
acute adverse effects, TC patients face long term side
effects, including increased risk of medical disorders such
as cardiovascular disease [27-29]. Furthermore, an under-
standing of the mechanisms that underlie the development
of sequelae after cisplatin-based therapy has broader impli-
cations because platinum agents are now one of the most
widely used groups of cytotoxic drugs worldwide [3].
Knowledge concerning biological effects of cancer treat-
ment on physiological outcomes related to exercise is very
limited, and studies elucidating the effect of anticancer
treatment on exercise physiological outcomes are in
demand [30-35]. It is the main aim of the PROTRACT
study to investigate the muscular side effects of BEP treat-
ment in TC patients. Even though it is well established that
chemotherapy induces degenerative effects in most body
tissues [36,37], only few studies so far have been presented
to elucidate the potential damaging effects of antineoplastic
agents on the skeletal musculature [38-40]. Effects of Dox-
orubicin, an antracycline extensively used in breast cancer
treatment, have been examined in a number of animal stu-
dies, and the myotoxic effect has in part been explained by
increased oxidative stress by reactive oxygen species (ROS)
causing muscular dysfunction [41,42]. In a recent study
Smuder and colleagues showed that exercise protects
against this myotoxicity in rats [40,43]. To this point no
human studies have assessed intramuscular effects of che-
motherapy, however Jones and colleges currently have 2
studies ongoing evaluating muscular effects through collec-
tion of muscle biopsies [44,45]. These two studies will ana-
lyze muscular morphology in lung cancer- and breast
cancer patients respectively, however both studies investi-
gate aerobic exercise interventions, and will mainly focus
on the effect on the cardio-respiratory system and the
oxygen cascade. Furthermore these studies include only
cancer patients who have terminated adjuvant treatment;
therefore these patients are not experiencing the concomi-
tant degenerative effects of the anticancer treatment.
We have chosen to investigate the effect of a structured
HIPRT program initiated at day 1 of the treatment, to
avoid a pre-intervention deterioration. Carrying out an
exercise program during the course of a very toxic treat-
ment obviously causes practical challenges due to side-
effects like nausea or febrile neutropenia, which may lead
to infections. Also TC patients are hospitalized for the first
5 days of each cycle where they receive treatment (che-
motherapy and fluids) for 8 to 10 hours per day. This
design however, allows us to investigate the direct effects
of antineoplastic therapy on skeletal muscle. To minimize
confounding factors it is important to eliminate the effect
of the tumor itself as much as possible. For this purpose
TC patients are optimal, as they have a very responsive
tumor and most likely the disease has only minor influence
after the first cycle. TC patients, however, may be affected
by the presence of hypogonadism, which can significantly
affect muscular adaptations to resistance exercise. Up to
50% of leydig cells are lost at unilateral orchiectomy [46],
and subnormal levels of testosterone have been found in
long term TC survivors [47,48]. In healthy subject it has
been shown that suppression of testosterone attenuates the
response to resistance training [49], however whether TC
patients undergoing chemotherapy experience attenuated
exercise response because of treatment induced hypogo-
nadism is currently unknown.
The literature concerning exercise as a concomitant
intervention alongside anticancer regimes, i.e. chemother-
apy, is constantly growing as an increasing number of stu-
dies show positive effects of exercise on physical and
psychosocial outcomes. However by far the majority of
exercise studies in cancer patients has focused on aerobic
training, with limited studies investigating a combined
aerobic/resistance program [26] or resistance training
alone [50-52]. The relative absence of exercise trials focus-
ing on lean body mass (LBM) is curious, since LBM is
regarded an important physiological parameter in overall
health profile. When administering chemotherapy in can-
cer treatment, dose is calculated pr body surface area (in
m
2), only taking into account the patient’sh e i g h ta n d
weight. However, it has been shown that LBM is an inde-
pendent determinant of 5-Fluorouracil-based toxicity [53],
and sarcopenia has been shown to be an independent pre-
dictor of toxicity and Time to Progression in breast cancer
patients [54]. This indicates the importance of maintaining
(or improving) LBM during chemotherapy treatment,
hence increasing demands for interventions to improve
this specific physiological parameter.
When comparing exercise-oncology studies to exercise
studies in healthy subjects, a methodological gap exists in
the muscular strength assessment measures. Direct or esti-
mated 1RM measures are almost unanimously used to
evaluate maximum muscle strength in exercise-oncology
trials. Arguments can be made that the 1RM test mainly
evaluates the neurological adaptation to the exercise pro-
gram, and may overestimate the actual effect on muscle
strength due to simple familiarization to the specific
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of resistance exercise intervention is to increase muscle
mass, the 1RM assessment may seem less than optimal. In
the PROTRACT study we introduce 2 golden standard
measurements for muscle strength and function, MVC
and LEP tests respectively, to evaluate the effect on these
parameters. These are chosen to ensure valid measure-
ments of muscle strength, both regarding a morphological
and a neuromuscular component, whilst minimizing the
effect of familiarization.
Summary
With the increasing interest in the research field of exer-
cise-oncology, more studies are now focusing on the appli-
cation of exercise as a concomitant intervention alongside
anti-cancer therapies. Even though exercise is widely
recommended, information concerning the biological/
patho-physiological effects of anti-cancer therapies, and
especially systemic treatments like chemotherapy, on the
skeletal musculature is very limited. To our knowledge no
studies have yet reported muscular data from exercise
trials in cancer patients undergoing active treatment.
Furthermore, there is a distinct need for oncology-exercise
trials including male cancer patients, since by far the
majority of studies focus on women with breast cancer.
To our knowledge the PROTRACT study is the first study
designed specifically to address the challenges related to
the adverse effects of antineoplastic treatment on physical
capacity, muscle mass and muscular function in testicular
cancer patients undergoing chemotherapy.
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